['I. DUE TO THE COMPETITION OF SALICYLATE WITH OTHER DRUGS FOR BINDING TO SERUM ALBUMIN THE FOLLOWING DRUG INTERACTIONS MAY OCCUR:', 'DRUG', 'DESCRIPTION OF INTERACTION', 'SULFONYLUREAS', 'HYPOGLYCEMIA POTENTIATED.', 'METHOTREXATE', 'DECREASES TUBULAR REABSORPTION; CLINICAL TOXICITY FROM METHOTREXATE CAN RESULT.', 'ORAL ANTICOAGULANTS', 'INCREASED BLEEDING.', 'II. DRUGS CHANGING SALICYLATE LEVELS BY ALTERING RENAL TUBULAR REABSORPTION:', 'DRUG', 'DESCRIPTION OF INTERACTION', 'CORTICOSTEROIDS', 'DECREASES PLASMA SALICYLATE LEVEL; TAPERING DOSES OF STEROIDS MAY PROMOTE SALICYLISM.', 'ACIDIFYING AGENTS', 'INCREASES PLASMA SALICYLATE LEVELS.', 'ALKANIZING AGENTS', 'DECREASED PLASMA SALICYLATE LEVELS.', 'III. DRUGS WITH COMPLICATED INTERACTIONS WITH SALICYLATES:', 'DRUG', 'DESCRIPTION OF INTERACTION', 'HEPARIN', 'SALICYLATE DECREASES PLATELET ADHESIVENESS AND INTERFERES WITH HEMOSTASIS IN HEPARIN-TREATED PATIENTS.', 'PYRAZINAMIDE', 'INHIBITS PYRAZINAMIDE-INDUCED HYPERURICEMIA.', 'URICOSURIC AGENTS', 'EFFECT OF PROBENEMIDE, SULFINPYRAZONE AND PHENYLBUTAZONE INHIBITED.', 'THE FOLLOWING ALTERATIONS OF LABORATORY TESTS HAVE BEEN REPORTED DURING SALICYLATE THERAPY:', 'LABORATORY TESTS', 'EFFECT OF SALICYLATES', 'THYROID FUNCTION', 'DECREASED PBI; INCREASED T 3 UPTAKE.', 'URINARY SUGAR', 'FALSE NEGATIVE WITH GLUCOSE OXIDASE; FALSE POSITIVE WITH CLINITEST WITH HIGH-DOSE SALICYLATE THERAPY (2-5G Q.D.).', '5-HYDROXYINDOLE ACETIC ACID', 'FALSE NEGATIVE WITH FLUOROMETRIC TEST.', 'ACETONE KETONE BODIES', 'FALSE POSITIVE FECI 3 IN GERHARDT REACTION; RED COLOR PERSISTS WITH BOILING.', '17-OH CORTICOSTEROIDS', 'FALSE REDUCED VALUES WITH >4.8G Q.D. SALICYLATE.', 'VANILMANDELIC ACID', 'FALSE REDUCED VALUES.', 'URIC ACID', 'MAY INCREASE OR DECREASE DEPENDING ON DOSE.', 'PROTHROMBIN', 'DECREASED LEVELS; SLIGHTLY INCREASED PROTHROMBIN TIME.']